Sound Pharmaceuticals Completes Enrollment in Phase 3 SPI-1005 Study for Ménière’s Disease
SEATTLE, WASHINGTON – Sound Pharmaceuticals, a private biotechnology firm, has announced the successful completion of enrollment in its second Phase 3 open-label study for SPI-1005, an investigational oral therapy targeting…
